Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced its commitment to improving the lives of Wilson disease patients around the world.
Valeant has agreed to provide $100,000 to fund enhanced patient awareness and research into this debilitating disease. This charitable contribution will be used to further the ongoing mission of the Wilson Disease Association (WDA) to facilitate and promote the identification, education, treatment and support of patients and other individuals affected by the disease. In addition to this contribution, Valeant has committed to augmenting its patient services hub for Wilson disease to improve both the patient and prescriber experience under the Valeant Coverage Plus Program. Valeant also plans to collaborate with the WDA to develop an educational app for iPhone and iPad to serve as a resource platform for patients.
“We are very pleased to support the Wilson Disease Association, an important organization that is dedicated to a critical therapeutic area,” said Joseph C. Papa, chairman and chief executive officer of Valeant. “This collaboration underscores our focus on improving the lives of patients around the world, especially those affected by Wilson disease.”
Recommended Article: Canaccord Analyst Cautious on Valeant Pharmaceuticals Intl Inc (VRX) Ahead of 2Q Financial Results; Here’s Why
“We greatly appreciate the contributions that Valeant is making to Wilson disease patients,” said Mary L. Graper, president of the Wilson Disease Association. “Enhancing awareness and promoting education around this disease is critical, and we believe that Valeant’s efforts will allow us to do more to ensure the well-being of patients and their families.” (Original Source)
Shares of Valeant closed today at $22.45, up $0.49 or 2.23%. VRX has a 1-year high of $253.62 and a 1-year low of $18.55. The stock’s 50-day moving average is $22.17 and its 200-day moving average is $41.91.
On the ratings front, VRX has been the subject of a number of recent research reports. In a report issued on August 3, Morgan Stanley analyst David Risinger maintained a Hold rating on VRX, with a price target of $33, which implies an upside of 47.0% from current levels. Separately, on August 1, Wells Fargo’s David Maris reiterated a Sell rating on the stock and has a price target of $19.50.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Risinger and David Maris have a total average return of 1.2% and 10.4% respectively. Risinger has a success rate of 57.8% and is ranked #1786 out of 4019 analysts, while Maris has a success rate of 72.3% and is ranked #388.
The street is mostly Neutral on VRX stock. Out of 17 analysts who cover the stock, 9 suggest a Hold rating , 5 suggest a Buy and 3 recommend to Sell the stock. The 12-month average price target assigned to the stock is $33.90, which implies an upside of 51.0% from current levels.
Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. The company operates through two operating and reportable segments: (i) Developed Markets and (ii) Emerging Markets. The Developed Markets segment consists of (i) sales in the U.S. of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of eye health, dermatology and podiatry, aesthetics and dentistry, (ii) sales in the U.S. of pharmaceutical products indicated for the treatment of neurological and other diseases, as well as alliance revenue from the licensing of various products it developed or acquired, and (iii) pharmaceutical products, OTC products, and medical device products sold in Canada, Australia, New Zealand, Western Europe and Japan. The Emerging Markets segment consists of branded generic pharmaceutical products and pharmaceuticals, OTC products, and medical device products. Products are sold primarily in Central and Eastern Europe (primarily Poland and Russia), Asia, Latin America (Mexico, Brazil, and Argentina and exports out of Mexico to other Latin American markets), Africa and the Middle East.